Xeris Pharmaceuticals Inc. (XERS) Misses Q4 EPS by 1c, provides guidance

Xeris Pharmaceuticals Inc. (NASDAQ: XERS) reported Q4 EPS of ($0.10), $0.01 worse than the analyst estimate of ($0.09). Revenue for the quarter came in at $44.39 million versus the consensus estimate of $43.11 million.

GUIDANCE:

Xeris Pharmaceuticals Inc. sees FY2024 revenue of $170-200 million, versus the consensus of $184.1 million. And year-end cash, cash equivalents, and short-term investments of $55M-$75M

For earnings history and earnings-related data on Xeris Pharmaceuticals Inc. (XERS) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• AeroVironment restates quarterly financials, citing $89M goodwill error
• KeyBanc Downgrades Primoris Services Corporation (PRIM) to Sector Weight